Hyperion Capital Advisors LP Grows Position in Icon Plc $ICLR

Hyperion Capital Advisors LP raised its stake in Icon Plc (NASDAQ:ICLR) by 10.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,474 shares of the medical research company’s stock after acquiring an additional 4,549 shares during the period. Icon makes up 4.4% of Hyperion Capital Advisors LP’s portfolio, making the stock its 10th biggest position. Hyperion Capital Advisors LP’s holdings in Icon were worth $7,051,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of the stock. SVB Wealth LLC bought a new position in Icon in the 1st quarter worth about $28,000. Ameritas Advisory Services LLC bought a new stake in Icon during the 2nd quarter valued at about $48,000. LRI Investments LLC purchased a new position in Icon in the second quarter worth about $49,000. Blue Trust Inc. lifted its stake in shares of Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after buying an additional 120 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Icon by 40,800.0% in the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock worth $59,000 after buying an additional 408 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Price Performance

NASDAQ ICLR opened at $186.58 on Friday. The stock has a market capitalization of $15.07 billion, a price-to-earnings ratio of 25.25, a PEG ratio of 3.48 and a beta of 1.25. Icon Plc has a 1-year low of $125.10 and a 1-year high of $228.29. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The business’s fifty day moving average price is $176.51 and its 200-day moving average price is $166.43.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. UBS Group set a $220.00 price target on shares of Icon in a research report on Friday, October 24th. Rothschild & Co Redburn upgraded Icon from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $184.00 to $236.00 in a research note on Wednesday, September 3rd. TD Cowen lowered their price target on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a report on Friday, October 24th. Robert W. Baird set a $220.00 price objective on Icon in a report on Friday, October 24th. Finally, Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Icon currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.00.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.